Srinija Drugs Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 23-10-2024
- Paid Up Capital ₹ 6.00 M
as on 23-10-2024
- Company Age 24 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.44 Cr
as on 23-10-2024
- Satisfied Charges ₹ 1.24 Cr
as on 23-10-2024
- Revenue -2.46%
(FY 2023)
- Profit -46.13%
(FY 2023)
- Ebitda -22.38%
(FY 2023)
- Net Worth 10.31%
(FY 2023)
- Total Assets 24.37%
(FY 2023)
About Srinija Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 6.00 M.
The company currently has active open charges totaling ₹2.44 Cr. The company has closed loans amounting to ₹1.24 Cr, as per Ministry of Corporate Affairs (MCA) records.
Laxmanarao Talluri, Venkata Donavalli, Bulli Nekkanti, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24233AP2000PTC034263
- Company No.
034263
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Apr 2000
- Date of AGM
04 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Krishna, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Srinija Drugs Private Limited offer?
Srinija Drugs Private Limited offers a wide range of products and services, including Organic Compounds, 1-Hydroxybenzotriazole.
Who are the key members and board of directors at Srinija Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bulli Nekkanti  | Managing Director | 17-Apr-2000 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Laxmanarao Talluri | Director | 17-Apr-2000 | Current |
| Venkata Donavalli | Director | 17-Apr-2000 | Current |
| Nekkanti Saraswathi | Director | 03-Jan-2024 | Current |
| Anantha Talluri | Director | 03-Jan-2024 | Current |
| Venkata Donavalli | Director | 03-Jan-2024 | Current |
Financial Performance of Srinija Drugs.
Srinija Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.46% decrease. The company also saw a substantial fall in profitability, with a 46.13% decrease in profit. The company's net worth Soared by an impressive increase of 10.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srinija Drugs?
In 2023, Srinija Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Srinija Life Sciences Private LimitedActive 3 years 27 daysLaxmanarao Talluri, Venkata Donavalli and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Sep 2014 | ₹2.44 Cr | Open |
Oriental Bank Of Commerce Creation Date: 12 Aug 2011 | ₹9.00 M | Satisfied |
Indusind Bank Creation Date: 01 Mar 2006 | ₹3.40 M | Satisfied |
How Many Employees Work at Srinija Drugs?
Srinija Drugs has a workforce of 19 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srinija Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srinija Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
